Marvell isn't a quarter-to-quarter story and analysts are advising investors to treat it with longer-term targets in mind.
Marvell is having trouble moving forecasts as trade uncertainties temper optimism.
There's apparently no key man risk at Burlington.
Burlington stock is bouncing big after a big earnings beat, capitalizing on the chaos in the retail sector.
Here's why Okta could accelerate, and what could derail the optimism.
Outlining Okta's earnings prospects on Wednesday is a tale of tempting TAM and troublesome valuation.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Salesforce is characteristically sustaining strength despite a heap of headwinds.
Nordstrom may be nearing inflection but seeing is believing.